Cargando…

Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression

In chronic kidney disease (CKD), accumulation of uremic toxins is associated with an increased risk of CKD progression. Some uremic toxins result from nutrient processing by gut microbiota, yielding precursors of uremic toxins or uremic toxins themselves, such as trimethylamine N-Oxide (TMAO), p-cre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castillo-Rodriguez, Esmeralda, Fernandez-Prado, Raul, Esteras, Raquel, Perez-Gomez, Maria Vanessa, Gracia-Iguacel, Carolina, Fernandez-Fernandez, Beatriz, Kanbay, Mehmet, Tejedor, Alberto, Lazaro, Alberto, Ruiz-Ortega, Marta, Gonzalez-Parra, Emilio, Sanz, Ana B., Ortiz, Alberto, Sanchez-Niño, Maria Dolores
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070989/ https://www.ncbi.nlm.nih.gov/pubmed/30029499 http://dx.doi.org/10.3390/toxins10070300

Ejemplares similares

Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease
por: Fernandez-Prado, Raul, et al.
Publicado: (2017)

Clarifying the concept of chronic kidney disease for non-nephrologists
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2019)

The chaos of hypertension guidelines for chronic kidney disease patients
por: Castillo-Rodriguez, Esmeralda, et al.
Publicado: (2019)

Phosphate, Microbiota and CKD
por: Favero, Chiara, et al.
Publicado: (2021)

Who killed Bruce Lee? The hyponatraemia hypothesis
por: Villalvazo, Priscila, et al.
Publicado: (2022)

The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality
por: Gonzalez-Martin, Guillermo, et al.
Publicado: (2020)

Inflammatory Cytokines as Uremic Toxins: “Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son”
por: Castillo-Rodríguez, Esmeralda, et al.
Publicado: (2017)

Klotho, the elusive kidney-derived anti-ageing factor
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2019)

Phosphorus and Nutrition in Chronic Kidney Disease
por: González-Parra, Emilio, et al.
Publicado: (2012)

Low Intracellular Water, Overhydration, and Mortality in Hemodialysis Patients
por: Gracia-Iguacel, Carolina, et al.
Publicado: (2020)

Often forgotten, transport modality to dialysis may be life-saving
por: Fernandez-Prado, Raul, et al.
Publicado: (2020)

Chronodisruption: A Poorly Recognized Feature of CKD
por: Carriazo, Sol, et al.
Publicado: (2020)

Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2017)

Women and renal replacement therapy in Europe: lower incidence, equal access to transplantation, longer survival than men
por: Fernandez-Prado, Raul, et al.
Publicado: (2018)

Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2015)

Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease
por: Fernandez-Prado, Raul, et al.
Publicado: (2020)

Gender, Albuminuria and Chronic Kidney Disease Progression in Treated Diabetic Kidney Disease
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

MXRA5 is a TGF‐β1‐regulated human protein with anti‐inflammatory and anti‐fibrotic properties
por: Poveda, Jonay, et al.
Publicado: (2016)

A sudden decrease in serum creatinine and estimated glomerular filtration rate: clinical implications of administrative gender assignment in transgender persons
por: Fernandez-Prado, Raul, et al.
Publicado: (2019)

Podocyte and tubular involvement in AngioJet-induced kidney injury
por: Esteras, Raquel, et al.
Publicado: (2019)

Osteoprotegerin in Exosome-Like Vesicles from Human Cultured Tubular Cells and Urine
por: Benito-Martin, Alberto, et al.
Publicado: (2013)

Modifiable Risk Factors for Increased Arterial Stiffness in Outpatient Nephrology
por: Elewa, Usama, et al.
Publicado: (2015)

Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer?
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2014)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

MYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy
por: Fernandez-Prado, Raul, et al.
Publicado: (2019)

Kidney disease and electrolytes in COVID-19: more than meets the eye
por: Carriazo, Sol, et al.
Publicado: (2020)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
por: Sarafidis, Pantelis, et al.
Publicado: (2023)

Tenofovir Nephrotoxicity: 2011 Update
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2011)

Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2018)

TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease
por: Poveda, Jonay, et al.
Publicado: (2013)

The role of endothelial glycocalyx in health and disease
por: Yilmaz, Onur, et al.
Publicado: (2019)

Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution
por: Kanbay, Mehmet, et al.
Publicado: (2022)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered
por: Ortiz, Alberto, et al.
Publicado: (2015)

Sarcopenia in CKD: a roadmap from basic pathogenetic mechanisms to clinical trials
por: Ortiz, Alberto, et al.
Publicado: (2019)

Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2018)

Air pollution and kidney disease: review of current evidence
por: Afsar, Baris, et al.
Publicado: (2018)

Regulated cell death pathways in kidney disease
por: Sanz, Ana B., et al.
Publicado: (2023)

Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease
por: Donate-Correa, Javier, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6vhk5iknp1j8r0jnr3d6ujuvm4